{"id":4634,"date":"2024-04-20T04:01:23","date_gmt":"2024-04-20T04:01:23","guid":{"rendered":"http:\/\/medexperts.pro\/?p=4634"},"modified":"2024-04-20T04:27:46","modified_gmt":"2024-04-20T04:27:46","slug":"inside-novo-nordisk-the-company-behind-ozempic-and-wegovy","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=4634","title":{"rendered":"Inside Novo Nordisk, the Company Behind Ozempic and Wegovy"},"content":{"rendered":"
<\/div>\n
\n
\n

Lars Fruergaard Jorgensen has a problem: Too many people want what he\u2019s selling.<\/p>\n

Mr. Jorgensen is the chief executive of Novo Nordisk, the Danish drugmaker. Even if the company isn\u2019t quite a household name, the TV jingle<\/a> for its best-selling drug \u2014 \u201cOh-oh-ohhh, Ozempic!\u201d \u2014 might ring in your ears. Across the United States, Novo Nordisk\u2019s diabetes and weight-loss drugs, Ozempic and Wegovy<\/a>, have soared to celebrity status and helped make the company Europe\u2019s most valuable public firm. It can\u2019t make enough of the drugs.<\/p>\n

Mr. Jorgensen\u2019s problem is one many top executives wouldn\u2019t mind, but the success caught him off guard. Last year, when the company was celebrating its centenary, Novo Nordisk\u2019s revenue jumped by a third, to 232 billion Danish kroner, or $33 billion.<\/p>\n

\u201cNobody had forecast this growth \u2014 no analyst, nobody in the company,\u201d Mr. Jorgensen said in a recent interview at the company\u2019s headquarters in a suburb of Copenhagen. \u201cNobody forecast a 100-year-old company would grow more than 30 percent,\u201d he said, seemingly torn between pride and amazement.<\/p>\n

For most of its 100 years Novo Nordisk has been focused on the steady business of treating diabetes, one of the world\u2019s most prevalent chronic diseases. Even today, it produces half the world\u2019s insulin. But the development of Ozempic and Wegovy has led to a bigger and bolder ambition to \u201cdefeat serious chronic diseases.\u201d That includes treating, and even preventing, obesity, which is linked to other health issues like heart and kidney diseases.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

By pursuing a much larger target than diabetes, the company expects to unlock the door to a multibillion-dollar market with nearly a billion potential patients. In the United States alone, more than 40 percent of adults are obese.<\/p>\n

And so the Danish drugmaker is undergoing vast changes \u2014 it\u2019s getting bigger, more international and closer to the heat of the spotlight. Mr. Jorgensen is trying to ramp up production to meet the huge demand for its weight-loss drugs, stay ahead of competition from Eli Lilly<\/a> and others and ensure the company\u2019s future so it can meet its lofty goal.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Lars Fruergaard Jorgensen has a problem: Too many people want what he\u2019s selling.Mr. Jorgensen is the chief executive of Novo Nordisk, the Danish drugmaker. Even if the company isn\u2019t quite a household name, the TV jingle for its best-selling drug \u2014 \u201cOh-oh-ohhh, Ozempic!\u201d \u2014 might ring in your ears. Across the United States, Novo Nordisk\u2019s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status and helped make the company Europe\u2019s most valuable public firm. It can\u2019t make enough of the drugs.Mr. Jorgensen\u2019s problem is one many top executives wouldn\u2019t mind, but the success caught him off guard. Last year, when the company was celebrating its centenary, Novo Nordisk\u2019s revenue jumped by a third, to 232 billion Danish kroner, or $33 billion.\u201cNobody had forecast this growth \u2014 no analyst, nobody in the company,\u201d Mr. Jorgensen said in a recent interview at the company\u2019s headquarters in a suburb of Copenhagen. \u201cNobody forecast a 100-year-old company would grow more than 30 percent,\u201d he said, seemingly torn between pride and amazement.For most of its 100 years Novo Nordisk has been focused on the steady business of treating diabetes, one of the world\u2019s most prevalent chronic diseases. Even today, it produces half the world\u2019s insulin. But the development of Ozempic and Wegovy has led to a bigger and bolder ambition to \u201cdefeat serious chronic diseases.\u201d That includes treating, and even preventing, obesity, which is linked to other health issues like heart and kidney diseases.By pursuing a much larger target than diabetes, the company expects to unlock the door to a multibillion-dollar market with nearly a billion potential patients. In the United States alone, more than 40 percent of adults are obese.And so the Danish drugmaker is undergoing vast changes \u2014 it\u2019s getting bigger, more international and closer to the heat of the spotlight. Mr. Jorgensen is trying to ramp up production to meet the huge demand for its weight-loss drugs, stay ahead of competition from Eli Lilly and others and ensure the company\u2019s future so it can meet its lofty goal.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":4636,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[],"class_list":["post-4634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/4634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4634"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/4634\/revisions"}],"predecessor-version":[{"id":4637,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/4634\/revisions\/4637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/4636"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}